American Rheumatology Network Tech Platform to Bolster Clinical Trials
American Rheumatology Network (ARN), a national group of more than 35 community-based physician practices, has launched ARN Clinical Research to speed drug development for rheumatology research.
ARN has more than 250 providers, 66 locations, and over 370,000 patients. ARN's sites have been involved in clinical trials for more than 25 years and have individually conducted over 1,500 rheumatology trials.
The organization has partnered with Trio Health on a technology-driven solution to develop a real-time integrated platform enabling drug manufacturers to rapidly achieve their goals.
Trio's MDX platform includes real-time access to patient data and physicians throughout the patient journey. The database encompasses 100 percent of the ARN sites with full EHR access and bi-directional data: the platform not only extracts transactional data, but also serves as a central hub for data supplementation and verification. Trio's clinical data team has real-time access to patient-level data to process unstructured data, eliminating the burden to ARN members' practices, the company said.
"The launch of this solution unifies ARN practices to deliver cutting-edge resources to support manufacturers' drug development efforts in the fight to transform rheumatologic diseases," said Michael Cooper, ARN's CEO, in a statement.
The newly formed ARN Clinical Research includes scientific steering committee, data scientists to generate evidence-based insights, and a clinical operations and analytics team. This platform is built to deploy new clinical research models, including decentralized and hybrid trials, pragmatic trials, and synthetic arms.
“The ARN Clinical Research gives us the ability to quickly identify patients — in hours vs. weeks — against protocols and to rapidly do clinical feasibility and source document verification,” said Ramita Tandon, Trio Health's chief operating officer, in a statement.
